A Phase 1 interventional study of Sotorasib in Healthy Participants, sponsored by Amgen. Completed at 4 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-14.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to compare the pharmacokinetics (PK) of sotorasib administered orally as 1 tablet under fasted conditions to sotorasib administered orally as 2 tablets under fasted conditions.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered sotorasib orally in the following order: Period 1 - as 1 tablet (test 1) Period 2 - as 2 tablets (reference) Period 3 - as 1 tablet (test 2)
Drug: Sotorasib
Participants will be administered sotorasib orally in the following order: Period 1 - as 2 tablets (reference) Period 2 - as 1 tablet (test 1) Period 3 - as 1 tablet (test 2)
Drug: Sotorasib
Oral Tablet
Also known as: AMG 510
Period 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Sotorasib
Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on the 1st day of each period (Days 1 and 4)
Period 1 and 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib
Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on the 1st day of each period (Days 1 and 4)
Period 1 and 2: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Sotorasib
Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on on the 1st day of each period (Days 1 and 4)
Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
A TEAE was defined as an adverse event (AE) that started during or after dosing, or started prior to dosing and increased in severity after dosing within each period. Clinically significant laboratory tests, 12-lead electrocardiogram (ECG), or vital sign results as assessed by the Investigator were also recorded as adverse events.
Time frame: Day 1 to Day 9
Period 3: Cmax of Sotorasib
Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on the 1st day of Period 3 (Day 7)
Period 3: AUClast of Sotorasib
Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on on the 1st day of Period 3 (Day 7)
Period 3: AUCinf of Sotorasib
Time frame: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on the 1st day of Period 3 (Day 7)
A total of 146 participants were enrolled with all participants randomized into Treatment Sequences AB and BA, including 14 participants that proceeded to receive Treatment C in the food effect substudy.
| Milestone | Treatment Sequence AB | Treatment Sequence BA | Treatment Sequence ABC | Treatment Sequence BAC |
|---|---|---|---|---|
| Started | 73 | 73 | 0 | 0 |
| Received at least 1 dose | 73 | 73 | 0 | 0 |
| Completed | 72 | 72 | 0 | 0 |
| Not completed | 1 | 1 | 0 | 0 |
| Withdrew: Miscellaneous | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Milestone | Treatment Sequence AB | Treatment Sequence BA | Treatment Sequence ABC | Treatment Sequence BAC |
|---|---|---|---|---|
| Started | 0 | 0 | 7 | 7 |
| Completed | 0 | 0 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
| ng/mL | Treatment A | Treatment B |
|---|---|---|
| Period 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Sotorasib | 4170 ± 75.0 | 4340 ± 65.5 |
| h*ng/mL | Treatment A | Treatment B |
|---|---|---|
| Period 1 and 2: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib | 15300 ± 56.2 | 15800 ± 54.6 |
| h*ng/mL | Treatment A | Treatment B |
|---|---|---|
| Period 1 and 2: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Sotorasib | 15500 ± 54.1 | 16100 ± 52.8 |
A TEAE was defined as an adverse event (AE) that started during or after dosing, or started prior to dosing and increased in severity after dosing within each period. Clinically significant laboratory tests, 12-lead electrocardiogram (ECG), or vital sign results as assessed by the Investigator were also recorded as adverse events.
| Participants | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE) | 3 | 10 | 0 |
| ng/mL | Treatment C |
|---|---|
| Period 3: Cmax of Sotorasib | 4530 ± 14.2 |
| h*ng/mL | Treatment C |
|---|---|
| Period 3: AUClast of Sotorasib | 19000 ± 20.3 |
| h*ng/mL | Treatment C |
|---|---|
| Period 3: AUCinf of Sotorasib | 19100 ± 20.0 |
Collected over Day 1 to Day 9. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | 0/146 (0%) | 0/146 (0%) | 3/146 (2.1%) |
| Treatment B | 0/146 (0%) | 0/146 (0%) | 10/146 (6.8%) |
| Treatment C | 0/14 (0%) | 0/14 (0%) | 0/14 (0%) |
| Event | Treatment A | Treatment B | Treatment C |
|---|---|---|---|
| HeadacheNervous system disorders | 0/146 | 3/146 | 0/14 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/146 | 2/146 | 0/14 |
| HaematomaVascular disorders | 0/146 | 2/146 | 0/14 |
| Abdominal discomfortGastrointestinal disorders | 0/146 | 1/146 | 0/14 |
| DiarrhoeaGastrointestinal disorders | 0/146 | 1/146 | 0/14 |
| NauseaGastrointestinal disorders | 0/146 | 1/146 | 0/14 |
| ToothacheGastrointestinal disorders | 0/146 | 1/146 | 0/14 |
| VomitingGastrointestinal disorders | 0/146 | 1/146 | 0/14 |
| Feeling coldGeneral disorders | 0/146 | 1/146 | 0/14 |
| Back painMusculoskeletal and connective tissue disorders | 1/146 | 0/146 | 0/14 |
| Age, Continuous(Years) | Treatment Sequence AB | Treatment Sequence BA | Total |
|---|---|---|---|
| Mean | 37.6 ± 11.1 | 39.2 ± 10.74 | 38.4 ± 10.91 |
| Sex: Female, Male(Participants) | Treatment Sequence AB | Treatment Sequence BA | Total |
|---|---|---|---|
| Female | 6 | 14 | 20 |
| Male | 67 | 59 | 126 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Sequence AB | Treatment Sequence BA | Total |
|---|---|---|---|
| Hispanic or Latino | 30 | 29 | 59 |
| Not Hispanic or Latino | 43 | 44 | 87 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Treatment Sequence AB | Treatment Sequence BA | Total |
|---|---|---|---|
| White | 41 | 44 | 85 |
| Black and African American | 27 | 25 | 52 |
| Asian | 3 | 4 | 7 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Multiple | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Mar 2022 to primary completion in Jul 2022, 3 months.
Results were first posted in Dec 2023, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotorasib